[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-364144-en":59,"doc-seo-364144-105":96},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":72,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":73,"language":74,"language_code":75,"site_id":76,"html_lang":75,"table_of_contents":77,"faqs":78,"seo_title":79,"seo_description":66,"update_tm":80,"read_time":81,"preview_page_count":82,"preview_urls":83},364144,3985747870733,"acoobca","https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Immune niche composed ofC1Q+ macrophages/SFRP2+ CAFs/CD8+ T cells drives immunotherapy response in HER2-positive gastric cancer","Immune checkpoint blockade combined with HER2-targeted regimens improves outcomes in HER2-positive gastric cancer, yet the spatial and molecular basis of the tumor immune microenvironment remains unclear. Spatial transcriptomics and single-cell RNA sequencing are applied to treatment-naïve HER2-positive and HER2-negative specimens to map tumor microenvironment architecture. The study finds C1Q+ macrophages interact with CD8+ T cells via Galectin-9, while SFRP2+ CAFs induce CD8+ exhaustion through CXCL12–CXCR4 signaling, shaping PD-1 response and suggesting a predictive biomarker.","Article [https://doi.org/10.1038/s41467-026-76544-x](https://doi.org/10.1038/s41467-026-76544-x)  \nImmune niche composed ofC1Q+ macrophages/SFRP2+ CAFs/CD8+ T cells drives immunotherapy response in HER2-positive gastric cancer  \n\n| Received: 15 January 2026\u003Cbr>Accepted: 29 July 2026\u003Cbr>| Yuhan Liao1,2,3,7, Xinhua Chen4,7, Haiyun Chen2,3,7, Lunbo Xie2,3, Yunfei Zhi 5, Hao Xu2,3, Xinghua Zhuo2,3, Shupeng Hu6, Liping Zhao6, Chuang Lin2,3, Yaoying Li2,3 & Liang Zhao 1,2,3  |  |\n| --- | --- | --- |\n| | Human epidermal growth factor receptor 2 (HER2) expression is a distinctive feature of a subgroup of gastric cancer (GC) but the underpinning characteristics ofthe immune microenvironment and mechanisms remain unclear. In the study, spatial transcriptomics and single-cell RNA sequencing are used on treatment-naïve HER2-positive and HER2-negative GC specimens to characterize the tumor microenvironment and spatial architecture with the aim of deﬁning how HER2 status shapes the tumor immune microenvironment (TIME) and its cellular interactions. We ﬁnd that C1Q⁺ macrophages spatially and functionally interact with CD8⁺ T cells via Galectin-9 (LGALS9), which is downregulated in HER2-positive tumors. Knocking down LGALS9 enhancesCD8⁺ T cell function and suppresses tumor growth in a CD8⁺ T celldependent manner, further ampliﬁed by anti-PD-1 treatment. Conversely, SFRP2⁺ cancer-associated ﬁbroblasts (CAF) promote CD8⁺ T cell exhaustion through CXCL12-CXCR4 signaling, and knocking down CXCL12 reverses this immunosuppressive effect. HER2-positive tumors are characterized by an immune-favorable niche enriched in C1Q⁺ macrophages and CD8⁺ T effector memory cells but a decrease in SFRP2⁺ CAFs, suggesting its potential as a predictive biomarker for response to combined anti-PD-1 and anti-HER2 therapies. These ﬁndings provide insight into the spatial and immune landscape of HER2-associated GC and may inform future precision treatment strategies. |  |\n| Gastric cancer (GC) constitutes a major global health burden, predominantly in East Asian nations1,2. In 2020, GC recorded over one million new cases and caused approximately 768,000 deaths globally, making it the ﬁfth most common cancer and the fourth leading cause of cancer-related mortality worldwide3,4. Human epidermal growth factor receptor 2 (HER2) represents a pivotal therapeutic target in GC5, |  | with an estimated positivity rate ranging from 15 to 20% among affected patients. HER2-positive GC exhibits high malignancy and poses major challenges due to variable responses and complex resistance mechanisms to targeted therapies such as trastuzumab, highlighting the need for further investigation into its molecular and immune features6–8. |\n\nA full list of afﬁliations appears at the end of the paper. e-mail: [liangsmu@foxmail.com](liangsmu@foxmail.com)  \nRecently, the addition of immune checkpoint blockade (ICB) to HER2-targeted regimens has shown promising results9–12. In the phase III KEYNOTE-811 trial, ﬁrst-line pembrolizumab combined with trastuzumab and chemotherapy signiﬁcantly enhanced objective response rates in metastatic HER2-positive gastric and gastroesophageal junction adenocarcinoma compared with trastuzumab and chemotherapy alone. The treatment response indicates that both the immune microenvironment and spatial heterogeneity of HER2-associated GC may play a combined role in shaping therapeutic outcomes. However, its underlying mechanism is still unclear. Speciﬁcally, HER2 overexpression has been shown to inﬂuence immune signaling and cytokine networks in cancer cells, which can, in turn, modulate immune cell recruitment and function independent of antibody treatment. HER2 signaling promotes the secretion of chemokines such as CCL2, which recruit monocytes and drive their polarization into tumor-associated macrophages (TAMs). Consistently, immunosuppressive TAM subsets are enriched in HER2-positive GC and are associated with poor prognosis13. In addition, HER2 suppresses STING ex","cbCaitQoBd5mrJ6T","https://ap.wps.com/l/cbCaitQoBd5mrJ6T","pdf",9903009,18,23,"English","en",105,"# Results\n## ST and scRNA-seq analyses revealed the spatial heterogeneity and immune microenvironment in HER2-positive GC","[{\"question\":\"What methods are used to study HER2-associated gastric cancer immune microenvironment?\",\"answer\":\"Spatial transcriptomics and single-cell RNA sequencing are used on treatment-naïve HER2-positive and HER2-negative specimens to characterize the tumor microenvironment and spatial architecture.\"},{\"question\":\"How do C1Q+ macrophages influence CD8+ T cells in HER2-positive tumors?\",\"answer\":\"C1Q+ macrophages spatially and functionally interact with CD8+ T cells through Galectin-9 (LGALS9), and LGALS9 is downregulated in HER2-positive tumors.\"},{\"question\":\"How do SFRP2+ CAFs affect CD8+ T cells and immunotherapy response?\",\"answer\":\"SFRP2+ cancer-associated fibroblasts promote CD8+ T cell exhaustion via CXCL12–CXCR4 signaling. Knocking down CXCL12 reverses the immunosuppressive effect, supporting the role of CAFs in shaping PD-1 blockade response.\"}]","Immune niche composed ofC1Q+ macrophages/SFRP2+ CAFs/CD8+ T cells drives immunotherapy response in HER2-positive gastric cancer | PDF",1790156010,58,3,[84,88,92],{"page_no":8,"url":85,"width":86,"height":87},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/d4803ae36a2cfcf5fbaf344cd747bdef.webp",983,1306,{"page_no":14,"url":89,"width":90,"height":91},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/3f53a4fd5a2daf86601d9d721329d21d.webp",982,1304,{"page_no":82,"url":93,"width":94,"height":95},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/2a184ff45dcfa69745c5ee4d6f3ff0fd.webp",981,1303,{"code":4,"msg":97,"data":98},"ok",{"site_id":76,"language":75,"slug":99,"title":65,"keywords":100,"description":66,"schema_data":101,"social_meta":154,"head_meta":156,"extra_data":158,"updated_unix":159},"immune-niche-composed-ofc1q-macrophagessfrp2-cafscd8-t-cells-drives-immunotherapy-response-in-her2-positive-gastric-cancer","",{"@graph":102,"@context":153},[103,116,136],{"@type":104,"itemListElement":105},"BreadcrumbList",[106,110,112,114],{"item":107,"name":108,"@type":109,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":111,"name":9,"@type":109,"position":14},"https://docshare.wps.com/document/",{"item":113,"name":40,"@type":109,"position":82},"https://docshare.wps.com/document/research-report/",{"item":115,"name":65,"@type":109,"position":19},"https://docshare.wps.com/document/immune-niche-composed-ofc1q-macrophagessfrp2-cafscd8-t-cells-drives-immunotherapy-response-in-her2-positive-gastric-cancer/364144/",{"url":115,"name":65,"@type":117,"image":118,"author":123,"headline":65,"publisher":125,"fileFormat":128,"inLanguage":75,"description":66,"dateModified":129,"datePublished":130,"encodingFormat":128,"isAccessibleForFree":131,"interactionStatistic":132},"DigitalDocument",{"url":119,"@type":120,"width":121,"height":122},"https://docshare.wps.com/thumbnails/immune-niche-composed-ofc1q-macrophagessfrp2-cafscd8-t-cells-drives-immunotherapy-response-in-her2-positive-gastric-cancer/364144.png","ImageObject",300,407,{"name":63,"@type":124},"Person",{"url":107,"name":126,"@type":127},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":133,"interactionType":134,"userInteractionCount":72},"InteractionCounter",{"@type":135},"ViewAction",{"@type":137,"mainEntity":138},"FAQPage",[139,145,149],{"name":140,"@type":141,"acceptedAnswer":142},"What methods are used to study HER2-associated gastric cancer immune microenvironment?","Question",{"text":143,"@type":144},"Spatial transcriptomics and single-cell RNA sequencing are used on treatment-naïve HER2-positive and HER2-negative specimens to characterize the tumor microenvironment and spatial architecture.","Answer",{"name":146,"@type":141,"acceptedAnswer":147},"How do C1Q+ macrophages influence CD8+ T cells in HER2-positive tumors?",{"text":148,"@type":144},"C1Q+ macrophages spatially and functionally interact with CD8+ T cells through Galectin-9 (LGALS9), and LGALS9 is downregulated in HER2-positive tumors.",{"name":150,"@type":141,"acceptedAnswer":151},"How do SFRP2+ CAFs affect CD8+ T cells and immunotherapy response?",{"text":152,"@type":144},"SFRP2+ cancer-associated fibroblasts promote CD8+ T cell exhaustion via CXCL12–CXCR4 signaling. Knocking down CXCL12 reverses the immunosuppressive effect, supporting the role of CAFs in shaping PD-1 blockade response.","https://schema.org",{"og:url":115,"og:type":155,"og:title":65,"og:site_name":126,"og:description":66},"article",{"robots":157,"canonical":115},"index,follow",{"doc_id":61,"site_id":76},1790663748]